TD Asset Management Inc Increases Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

TD Asset Management Inc increased its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCRFree Report) by 3.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 157,258 shares of the company’s stock after purchasing an additional 5,082 shares during the quarter. TD Asset Management Inc owned approximately 0.34% of Structure Therapeutics worth $6,410,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its stake in Structure Therapeutics by 208.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock worth $177,000 after purchasing an additional 2,939 shares during the last quarter. Washington University purchased a new stake in Structure Therapeutics during the third quarter worth approximately $215,000. Barclays PLC lifted its stake in Structure Therapeutics by 415.2% during the third quarter. Barclays PLC now owns 5,832 shares of the company’s stock worth $294,000 after purchasing an additional 4,700 shares during the last quarter. Acuta Capital Partners LLC purchased a new stake in Structure Therapeutics during the third quarter worth approximately $252,000. Finally, Raymond James & Associates purchased a new stake in Structure Therapeutics during the fourth quarter worth approximately $233,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on GPCR. Lifesci Capital restated an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. JPMorgan Chase & Co. started coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Friday, May 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has a consensus rating of “Buy” and an average target price of $83.13.

Get Our Latest Stock Report on GPCR

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $54.29 on Wednesday. The stock’s 50 day simple moving average is $38.89 and its 200-day simple moving average is $42.64. Structure Therapeutics Inc. has a 12-month low of $25.57 and a 12-month high of $75.02.

Structure Therapeutics (NASDAQ:GPCRGet Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. On average, analysts forecast that Structure Therapeutics Inc. will post -0.94 earnings per share for the current year.

About Structure Therapeutics

(Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Featured Stories

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. (NASDAQ:GPCRFree Report).

Institutional Ownership by Quarter for Structure Therapeutics (NASDAQ:GPCR)

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.